9 news items
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
LEGN
13 May 24
these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide
Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
LEGN
22 Apr 24
is a testament to our innovative science and galvanizes our efforts to provide new options that will improve outcomes for patients and give hope
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
LEGN
22 Apr 24
Huang, Ph.D., Chief Executive Officer of Legend Biotech. "This approval is a testament to our innovative science and galvanizes our efforts to provide
sgvw2 proiizhd8lagc7
LEGN
11 Apr 24
these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide
f5d16zj2pxey0dc7yqoespvh711hz16ums
JNJ
LEGN
NVS
8 Apr 24
. Hematology, Johnson & Johnson Innovative Medicine. “We more than doubled manufacturing of Carvykti in 2023, we are striving to double again
ya5f04asi15c7dfey4izklnb76fa6lnaj0dxxscod9
LEGN
8 Apr 24
and progressive hematologic cancer that causes patients to relapse and become refractory to treatment, so new, innovative options are desperately
zch0g802 1nm0
LEGN
5 Apr 24
is an incurable and progressive hematologic cancer that causes patients to relapse and become refractory to treatment, so new, innovative options
- Prev
- 1
- Next